- Home
- HNVR vs NBTX Comparison
HNVR vs NBTX Comparison
Compare HNVR & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- NBTX
- Stock Information
- Founded
- HNVR 2008
- NBTX 2003
- Country
- HNVR United States
- NBTX France
- Employees
- HNVR N/A
- NBTX N/A
- Industry
- HNVR Commercial Banks
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- NBTX Health Care
- Exchange
- HNVR Nasdaq
- NBTX Nasdaq
- Market Cap
- HNVR 163.2M
- NBTX 178.7M
- IPO Year
- HNVR 2022
- NBTX 2020
- Fundamental
- Price
- HNVR $20.70
- NBTX $3.29
- Analyst Decision
- HNVR Buy
- NBTX Strong Buy
- Analyst Count
- HNVR 1
- NBTX 1
- Target Price
- HNVR $22.00
- NBTX $8.00
- AVG Volume (30 Days)
- HNVR 15.1K
- NBTX 11.4K
- Earning Date
- HNVR 04-29-2025
- NBTX 04-02-2025
- Dividend Yield
- HNVR 1.95%
- NBTX N/A
- EPS Growth
- HNVR N/A
- NBTX N/A
- EPS
- HNVR 1.66
- NBTX N/A
- Revenue
- HNVR $63,491,000.00
- NBTX N/A
- Revenue This Year
- HNVR N/A
- NBTX N/A
- Revenue Next Year
- HNVR $15.80
- NBTX $277.81
- P/E Ratio
- HNVR $12.47
- NBTX N/A
- Revenue Growth
- HNVR 5.04
- NBTX N/A
- 52 Week Low
- HNVR $13.62
- NBTX $2.76
- 52 Week High
- HNVR $27.14
- NBTX $7.51
- Technical
- Relative Strength Index (RSI)
- HNVR 46.68
- NBTX 46.34
- Support Level
- HNVR $18.60
- NBTX $3.28
- Resistance Level
- HNVR $21.05
- NBTX $3.53
- Average True Range (ATR)
- HNVR 1.22
- NBTX 0.18
- MACD
- HNVR 0.08
- NBTX 0.00
- Stochastic Oscillator
- HNVR 50.00
- NBTX 46.48
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.